Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 4/2020

01-04-2020 | Esophageal Cancer | Thoracic Oncology

How Many Nodes Need to be Removed to Make Esophagectomy an Adequate Cancer Operation, and Does the Number Change When a Patient has Chemoradiotherapy Before Surgery?

Authors: Jonathan C. Yeung, MD, Manjit S. Bains, MD, Arianna Barbetta, MD, Tamar Nobel, MD, Steven R. DeMeester, MD, Brian E. Louie, MD, Mark B. Orringer, MD, Linda W. Martin, MD, Rishindra M. Reddy, MD, Francisco Schlottmann, MD, Daniela Molena, MD

Published in: Annals of Surgical Oncology | Issue 4/2020

Login to get access

Abstract

Introduction and Design

Node dissection during esophagectomy is an important aspect of esophageal cancer staging. Controversy remains as to how many nodes need to be resected in order to properly stage a patient and whether the removal of more nodes carries a stage-independent survival benefit. A review of the literature performed by a group of experts in the subject may help define a minimum accepted number of lymph nodes to be resected in both primary surgery and post-induction therapy scenarios.

Results and Conclusions

The existing evidence generally supports the goal of obtaining a minimum of 15 lymph nodes for pathological examination in both primary surgery and post-induction therapy scenarios.
Appendix
Available only for authorised users
Literature
1.
Akiyama H, Tsurumaru M, Kawamura T, Ono Y. Principles of surgical treatment for carcinoma of the esophagus: analysis of lymph node involvement. Ann Surg. 1981;194:438–46.CrossRef
2.
Metzger R, Bollschweiler E, Vallbohmer D, Maish M, DeMeester TR, Holscher AH. High volume centers for esophagectomy: what is the number needed to achieve low postoperative mortality? Dis Esophagus. 2004;17:310–4.CrossRef
3.
Groth SS, Virnig BA, Whitson BA, et al. Determination of the minimum number of lymph nodes to examine to maximize survival in patients with esophageal carcinoma: data from the Surveillance Epidemiology and End Results database. J Thorac Cardiovasc Surg. 2010;139:612–20.CrossRef
4.
Greenstein AJ, Litle VR, Swanson SJ, Divino CM, Packer S, Wisnivesky JP. Effect of the number of lymph nodes sampled on postoperative survival of lymph node-negative esophageal cancer. Cancer. 2008;112:1239–46.CrossRef
5.
Schwarz RE, Smith DD. Clinical impact of lymphadenectomy extent in resectable esophageal cancer. J Gastrointest Surg. 2007;11:1384–93; discussion 1393–4.CrossRef
6.
Samson P, Puri V, Robinson C, et al. Clinical T2N0 Esophageal cancer: identifying pretreatment characteristics associated with pathologic upstaging and the potential role for induction therapy. Ann Thorac Surg. 2016;101:2102–11.CrossRef
7.
Peyre CG, Hagen JA, DeMeester SR, et al. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg. 2008;248:549–56.CrossRef
8.
Bollschweiler E, Baldus SE, Schroder W, Schneider PM, Holscher AH. Staging of esophageal carcinoma: length of tumor and number of involved regional lymph nodes. Are these independent prognostic factors? J Surg Oncol. 2006;94:355–63.CrossRef
9.
Rizk N, Venkatraman E, Park B, et al. The prognostic importance of the number of involved lymph nodes in esophageal cancer: implications for revisions of the American Joint Committee on Cancer staging system. J Thorac Cardiovasc Surg. 2006;132:1374–81.CrossRef
10.
Altorki NK, Zhou XK, Stiles B, et al. Total number of resected lymph nodes predicts survival in esophageal cancer. Ann Surg. 2008;248:221–6.CrossRef
11.
Rizk NP, Ishwaran H, Rice TW, et al. Optimum lymphadenectomy for esophageal cancer. Ann Surg. 2010;251:46–50.CrossRef
12.
Rice TW, Ishwaran H, Hofstetter WL, et al. Esophageal cancer: associations with (pN +) lymph node metastases. Ann Surg. 2017;265:122–9.CrossRef
13.
Lagergren J, Mattsson F, Zylstra J, et al. Extent of lymphadenectomy and prognosis after esophageal cancer surgery. JAMA Surg. 2016;151:32–9.CrossRef
14.
van der Schaaf M, Johar A, Wijnhoven B, Lagergren P, Lagergren J. Extent of lymph node removal during esophageal cancer surgery and survival. J Natl Cancer Inst. 2015;107:pii:djv043.
15.
Alatengbaolide, Lin D, Li Y, et al. Lymph node ratio is an independent prognostic factor in gastric cancer after curative resection (R0) regardless of the examined number of lymph nodes. Am J Clin Oncol. 2013;36:325–30.CrossRef
16.
Roberts TJ, Colevas AD, Hara W, Holsinger FC, Oakley-Girvan I, Divi V. Number of positive nodes is superior to the lymph node ratio and American Joint Committee on Cancer N staging for the prognosis of surgically treated head and neck squamous cell carcinomas. Cancer. 2016;122:1388–97.CrossRef
17.
Greenstein AJ, Litle VR, Swanson SJ, Divino CM, Packer S, Wisnivesky JP. Prognostic significance of the number of lymph node metastases in esophageal cancer. J Am Coll Surg. 2008;206:239–46.CrossRef
18.
Hagen JA, DeMeester SR, Peters JH, Chandrasoma P, DeMeester TR. Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Ann Surg. 2001;234:520–30; discussion 530–1.CrossRef
19.
Kubo A, Corley DA. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15:872–8.CrossRef
20.
Wu AH, Wan P, Bernstein L. A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States). Cancer Causes Control. 2001;12:721–32.CrossRef
21.
Hu Y, Hu C, Zhang H, Ping Y, Chen LQ. How does the number of resected lymph nodes influence TNM staging and prognosis for esophageal carcinoma? Ann Surg Oncol. 2010;17:784–90.CrossRef
22.
Peng J, Wang WP, Yuan Y, Wang ZQ, Wang Y, Chen LQ. Adequate lymphadenectomy in patients with oesophageal squamous cell carcinoma: resecting the minimal number of lymph node stations. Eur J Cardiothorac Surg. 2016;49:e141–6.CrossRef
23.
Veeramachaneni NK, Zoole JB, Decker PA, Putnam JB Jr, Meyers BF; American College of Surgeons Oncology Group ZT. Lymph node analysis in esophageal resection: American College of Surgeons Oncology Group Z0060 trial. Ann Thorac Surg. 2008;86:418–21; discussion 421.
24.
Abbassi-Ghadi N, Boshier PR, Goldin R, Hanna GB. Techniques to increase lymph node harvest from gastrointestinal cancer specimens: a systematic review and meta-analysis. Histopathology. 2012;61:531–42.CrossRef
25.
Oppedijk V, van der Gaast A, van Lanschot JJ, et al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol. 2014;32:385–91.CrossRef
26.
Markl B. Stage migration vs immunology: the lymph node count story in colon cancer. World J Gastroenterol. 2015;21:12218–33.CrossRef
27.
Luna RA, Dolan JP, Diggs BS, et al. Lymph node harvest during esophagectomy is not influenced by use of neoadjuvant therapy or clinical disease stage. J Gastrointest Surg. 2015;19:1201–7.CrossRef
28.
Taylor MD, LaPar DJ, Davis JP, et al. Induction chemoradiotherapy and surgery for esophageal cancer: survival benefit with downstaging. Ann Thorac Surg. 2013;96:225–30; discussion 230–1.CrossRef
29.
Mariette C, Piessen G, Briez N, Triboulet JP. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg. 2008;247:365–71.CrossRef
30.
Kauppila JH, Wahlin K, Lagergren P, Lagergren J. Neoadjuvant therapy in relation to lymphadenectomy and resection margins during surgery for oesophageal cancer. Sci Rep. 2018;8:446.CrossRef
31.
van der Werf LR, Dikken JL, van Berge Henegouwen MI, et al. A population-based study on lymph node retrieval in patients with esophageal cancer: results from the Dutch upper gastrointestinal cancer audit. Ann Surg Oncol. 2018;25:1211–20.CrossRef
32.
Brescia AA, Broderick SR, Crabtree TD, et al. Adjuvant therapy for positive nodes after induction therapy and resection of esophageal cancer. Ann Thorac Surg. 2016;101:200–8.CrossRef
33.
Hanna JM, Erhunmwunsee L, Berry M, et al. The prognostic importance of the number of dissected lymph nodes after induction chemoradiotherapy for esophageal cancer. Ann Thorac Surg. 2015;99:265–9.CrossRef
34.
Samson P, Puri V, Broderick S, Patterson GA, Meyers B, Crabtree T. Extent of lymphadenectomy is associated with improved overall survival after esophagectomy with or without induction therapy. Ann Thorac Surg. 2017;103:406–15.CrossRef
Metadata
Title
How Many Nodes Need to be Removed to Make Esophagectomy an Adequate Cancer Operation, and Does the Number Change When a Patient has Chemoradiotherapy Before Surgery?
Authors
Jonathan C. Yeung, MD
Manjit S. Bains, MD
Arianna Barbetta, MD
Tamar Nobel, MD
Steven R. DeMeester, MD
Brian E. Louie, MD
Mark B. Orringer, MD
Linda W. Martin, MD
Rishindra M. Reddy, MD
Francisco Schlottmann, MD
Daniela Molena, MD
Publication date
01-04-2020
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 4/2020
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07870-2

Other articles of this Issue 4/2020

Annals of Surgical Oncology 4/2020 Go to the issue

ASO Author Reflections

ASO Author Reflections: Evaluation of Neoadjuvant Chemotherapy in the Treatment of High-Grade Upper Tract Urothelial Carcinoma

Hepatobiliary Tumors

A Machine-Based Approach to Preoperatively Identify Patients with the Most and Least Benefit Associated with Resection for Intrahepatic Cholangiocarcinoma: An International Multi-institutional Analysis of 1146 Patients

Peritoneal Surface Malignancy

Comment on “Diagnostic Laparoscopy as a Selection Tool for Patients with Colorectal Peritoneal Metastases to Prevent a Non-therapeutic Laparotomy During Cytoreductive Surgery”

Pancreatic Tumors

Neoadjuvant Therapy is Associated with Improved Survival in Borderline-Resectable Pancreatic Cancer

Translational Research and Biomarkers

Lymph Node Positivity in One-Step Nucleic Acid Amplification is a Prognostic Factor for Postoperative Cancer Recurrence in Patients with Stage II Colorectal Cancer: A Prospective, Multicenter Study

Breast Oncology

Primary Tumor Surgery for Patients with De Novo Stage IV Breast Cancer can Decrease Local Symptoms and Improve Quality of Life